Cell Culture

细胞培养

基本信息

批准号：
8335544
负责人：
MICHAEL V. SEIDEN
金额：
$ 12.09万
依托单位：
FOX CHASE CANCER CENTER
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-07-21 至 2014-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8335544
关键词：
Accounting Ammonium Sulfate Antibodies Antibody Formation Biochemical Biomedical Research Bioreactors Budgets Calendar Cancer Center Support Grant Cell Culture Techniques Cells Cloning Communities Comprehensive Cancer Center Consultations Culture Media Custom Development Economics Effectiveness Equipment Evaluation Faculty Fertilization Fox Chase Cancer Center Foxes Freezing Funding Genes Green Fluorescent Proteins Harvest Host Defense Human Resources Hybridomas Immune Individual Injection of therapeutic agent Instruction Knock-in Mouse Label Laboratories Liquid substance Location Mammalian Cell Methodology Mission Monoclonal Antibodies Mus Mycoplasma Nitrogen Parents Patients Peer Review Peripheral Play Population Precipitation Preparation Primary Cell Cultures Protocols documentation Reagent Recommendation Research Research Personnel Resource Sharing Resources Role Sampling Screening procedure Serum-Free Culture Media Services Site Source Surveys Talents Technical Expertise Techniques Technology Testing Time Tissue Culture Techniques Tissue Sample Training Transfection Vial device Western Blotting animal tissue anticancer research base cell bank cost cost effective design embryonic stem cell established cell line fetal bovine serum gel electrophoresis hybridoma production improved knockout gene operation performance tests programs research study

项目摘要

PROJECT SUMIVIARY (See instructions): Cell culture technology plays an essential role in modern cancer research. The Cell Culture Facility (CCF) serves as a customized pay-for-service Facility that provides expertise, technical support, reagents, equipment, liquid nitrogen storage, and training to increase the effectiveness and efficiency of using mammalian cell culture in Fox Chase Cancer Center (FCCC) laboratories. This Facility provides technical assistance and consultation services in tissue culture techniques, centralized liquid nitrogen banking, mycoplasma screening services, the preparation of custom and standard culture media and supplements, performance testing of fetal bovine serum, cell propagation, and technical support and supplies for mouse embryonic stem (ES) cell transfection and culture. Major efforts by the CCF include carrying out technically challenging techniques, such as the establishment of primary cell cultures from patient or animal tissue samples, hybridoma fusion and cloning services to generate monoclonal antibodies, and establishing gene "knockout" or "knock-in" Embryonic Stem (ES) cells to generate genetically manipulated mice. Since the last review the Center established a governing body for the CCSG supported Shared Resources called the Facility Parent Oversight Committee (FPOC). The FPOC recommended in 2008 that the CCF incorporate the Hybridoma Facility, which was previously approved as a distinct CCSG Facility. This merger has provided operational efficiencies by centrally locating the merged staff. Economic efficiencies have been achieved by reducing total staff by 2.05 FTE, and by presenting a reduced overall request from the CCSG. The merged CCSG budget request is $19,724 less than the combined levels approved for previously two distinct cores at the last review. In 2009, the Facility served 47 investigators with peer-reviewed funding. Service was provided to all five of the Center's CCSG Research Programs. Peer-reviewed, funded research accounted for 95.3% of CCF usage in calendar year 2009. Based on an annual quality survey administered by the FPOC, the Facility is highly regarded among faculty users, and received an "Outstanding to Excellent" rating at the last CCSG review. In the past five years, the demand for CCF services has remained strong. Importantly, the Facility supplies the FCCC community with valuable on-site expertise for a host of established cell culture protocols, consultation in the design and evaluation of experiments, training in cell culture methodologies, high quality culture media and supplements, and adaptable assistance delivered in a cost-effective manner.

项目摘要（参见说明）：细胞培养技术在现代癌症研究中发挥着至关重要的作用。细胞培养设施 (CCF) 作为定制的付费服务设施，提供专业知识、技术支持、试剂、设备、液氮储存和培训，以提高福克斯蔡斯癌症中心使用哺乳动物细胞培养的有效性和效率（FCCC）实验室。该设施提供组织培养技术、集中液氮库、支原体筛查服务、定制和标准培养基和补充剂的制备、胎牛血清的性能测试、细胞增殖以及小鼠胚胎干（ES）细胞转染和培养的技术支持和用品。 CCF 的主要工作包括开展技术上具有挑战性的技术，例如从患者或动物组织中建立原代细胞培养物样本、杂交瘤融合和克隆服务以产生单克隆抗体，并建立基因“敲除”或“敲入”胚胎干（ES）细胞以产生基因操纵小鼠。自上次审查以来，中心为 CCSG 支持的共享资源建立了一个管理机构，称为设施家长监督委员会 (FPOC)。 FPOC 在 2008 年建议 CCF 纳入杂交瘤设施，此前已被批准为独特的 CCSG 设施。此次合并通过集中安置合并后的员工提高了运营效率。通过将员工总数减少 2.05 名 FTE，并减少 CCSG 的总体要求，实现了经济效率。合并后的 CCSG 预算请求比上次审查时为之前两个不同核心批准的合并水平少了 19,724 美元。 2009 年，该机构为 47 名研究人员提供了同行评审资金。为该中心的所有五个 CCSG 研究项目提供了服务。 2009 日历年，经同行评审、资助的研究占 CCF 使用量的 95.3%。根据 FPOC 管理的年度质量调查，该设施在教师用户中受到高度评价，并获得了“优秀到优秀”的评价上次 CCSG 审核的评级。过去五年，CCF服务的需求依然强劲。重要的是，该设施为 FCCC 社区提供了许多已建立的细胞培养方案的宝贵现场专业知识、实验设计和评估方面的咨询、细胞培养方法培训、高质量培养基和补充剂，以及在一种具有成本效益的方式。